Abstract:Nicotinamide mononucleotide (NMN) has emerged as a promising therapeutic intervention for age-related disorders, including type 2 diabetes. In this study, we confirmed the previously observed effects of NMN treatment on glucose uptake and investigated its underlying mechanisms in various tissues and cell lines. Through the most comprehensive proteomic analysis to date, we discovered a series of novel organ-specific effects responsible for glucose uptake as measured by the IPGTT: adipose tissue growing (suggested by increased protein synthesis and degradation and mTOR proliferation signaling upregulation). Notably, we observed the upregulation of thermogenic UCP1, promoting enhanced glucose conversion to heat in intermuscular adipose tissue while showing a surprising repressive effect on mitochondrial biogenesis in muscle and the brain. Additionally, liver and muscle cells displayed a unique response, characterized by spliceosome downregulation and concurrent upregulation of chaperones, proteasomes, and ribosomes, leading to mildly impaired and energy-inefficient protein synthesis machinery. Furthermore, our findings revealed remarkable metabolic rewiring in the brain. This involved increased production of ketone bodies, downregulation of mitochondrial OXPHOS and TCA cycle components, as well as the induction of well-known fasting-associated effects. Collectively, our data elucidate the multifaceted nature of NMN action, highlighting its organ-specific effects and their role in improving glucose uptake. These findings deepen our understanding of NMN's therapeutic potential and pave the way for novel strategies in managing metabolic disorders.

Microbial creation of β-Nicotinamide mononucleotide and its regulation of lipid metabolism in the liver of high-fat diet mice

Nicotinamide Mononucleotide Improves the Alzheimer's Disease by Regulating Intestinal Microbiota

NMN Synbiotics: A Multifaceted Therapeutic Approach for Alzheimer’s Disease

Alleviation of hepatic insulin resistance and steatosis with NMN via improving endoplasmic reticulum–Mitochondria miscommunication in the liver of HFD mice

Nicotinamide N-methyltransferase Regulates Hepatic Nutrient Metabolism Through Sirt1 Protein Stabilization

Nicotinamide mononucleotide alters body composition and ameliorates metabolic disorders induced by a high-fat diet

Enhanced Production of Β-Nicotinamide Mononucleotide with Exogenous Nicotinamide Addition in Saccharomyces Boulardii-Ys01.

Host–microbiome interactions in nicotinamide mononucleotide (NMN) deamidation

Technology and functional insights into the nicotinamide mononucleotide for human health

NMN Maintains Intestinal Homeostasis by Regulating the Gut Microbiota

Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth

Integrated transcriptome and metabolome study reveal the therapeutic effects of nicotinamide riboside and nicotinamide mononucleotide on nonalcoholic fatty liver disease

De novo biosynthesis and nicotinamide biotransformation of nicotinamide mononucleotide by engineered yeast cells

Nicotinamide Mononucleotide Prevents Free Fatty Acid-Induced Reduction in Glucose Tolerance by Decreasing Insulin Clearance

Advances in the Synthesis and Physiological Metabolic Regulation of Nicotinamide Mononucleotide

An Overview of Engineering Microbial Production of Nicotinamide Mononucleotide.

Nicotinamide Mononucleotide (NMN) Works in Type 2 Diabetes through Unexpected Effects in Adipose Tissue, Not by Mitochondrial Biogenesis

Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice

Triple-Isotope Tracing for Pathway Discernment of NMN-Induced NAD+ Biosynthesis in Whole Mice

Biological production of nicotinamide mononucleotide: a review

High-Level Production of Nicotinamide Mononucleotide by Engineered Escherichia Coli.